Biological Determination of Calcitonin – Accredited In Vivo Bioassay for Potency, Safety and Batch Release for Global Markets
Our internationally accredited laboratory delivers a specialist biological determination of calcitonin service that provides pharmaceutical manufacturers, biopharmaceutical developers, contract testing organisations and regulatory affairs teams worldwide with the independent, traceable potency data required for the batch release, the stability monitoring and the registration of calcitonin drug substances and finished products. Every assay is conducted under the rigorous framework of ISO/IEC 17025, and each report bearing the ILAC mark is unconditionally accepted by regulatory authorities, notified bodies and supply‑chain partners in all major economies. The biological determination of calcitonin employs the standardised rat hypocalcaemic bioassay as prescribed by the United States Pharmacopeia General Chapter ⟨90⟩ and the European Pharmacopoeia monograph 2.5.8, in which the reduction of the serum calcium concentration in the rat following the subcutaneous injection of the test sample is quantitatively compared with that of a reference standard using a parallel‑line or a slope‑ratio statistical design. For a generic‑drug producer submitting an abbreviated new drug application to the FDA, an originator company performing the real‑time stability testing of a calcitonin injection, or a contract manufacturing organisation validating the potency of a new salmon‑calcitonin formulation, this service delivers the legally robust, defensible bioassay data that underpin the certificate of analysis, the demonstration of the lot‑to‑lot consistency and the global marketing‑authorisation compliance.
Product Samples We Regularly Subject to the Biological Determination of Calcitonin
The animal‑dosing and the blood‑sampling facilities, the automated clinical‑chemistry analysers, the calcium‑selective‑electrode systems and the statistical‑software platforms in our laboratory accommodate a variety of calcitonin‑containing products and their intermediates. The following categories represent the most frequently tested items:
- Calcitonin active pharmaceutical ingredients – synthetic salmon calcitonin, eel calcitonin and human calcitonin in the powder or the lyophilised form, characterised for the potency in the international units per milligram relative to the World Health Organisation International Standard or the pharmacopoeial reference standard
- Calcitonin injection solutions and the reconstituted lyophilised products – the multi‑dose vials, the pre‑filled syringes and the cartridge formulations that are intended for the subcutaneous or the intramuscular administration in the treatment of the post‑menopausal osteoporosis, the Paget’s disease of the bone and the hypercalcaemia of the malignancy
- Calcitonin nasal sprays – the metered‑dose, pump‑delivered intranasal formulations, evaluated for the delivered‑dose uniformity and the bioassay‑confirmed potency that is required for the product‑release and the stability‑indicating testing
- Stability‑study and the stress‑degradation samples – the calcitonin products that have been stored under the accelerated or the long‑term stability conditions, or that have been subjected to the thermal, the oxidative or the photolytic stress, submitted for the determination of the potency loss and the correlation with the chemical‑purity data
- Biosimilar and the follow‑on calcitonin products – the generic versions of the innovator calcitonin preparations, tested in the parallel‑bioassay design against the reference‑listed drug to demonstrate the bioequivalence of the potency and the absence of the product‑related impurities that could interfere with the biological activity
Rat Hypocalcaemic Bioassay Procedure According to USP ⟨90⟩ and Ph. Eur. 2.5.8
- Determination of the calcitonin potency by the subcutaneous injection and the measurement of the serum calcium concentration according to the harmonised principles of the USP General Chapter ⟨90⟩ (Calcitonin Bioassay) and the European Pharmacopoeia monograph 2.5.8 (Assay of Calcitonin): the healthy, young adult Sprague‑Dawley or Wistar rats of a single sex are randomly assigned to the standard‑dose and the test‑dose groups, and each rat receives a single subcutaneous injection of the calcitonin reference standard or the test sample solution at the precisely calibrated dose levels. At a defined time after the injection – typically 60 minutes – the blood is collected, the serum is separated, and the total calcium concentration is measured by a validated atomic‑absorption‑spectrophotometry, a colourimetric or an ion‑selective‑electrode method. The reduction of the serum calcium relative to the uninjected or the vehicle‑injected control animals is calculated, and the log‑dose–response relationship is established. The potency of the test sample in the international units per milligram or per millilitre is derived from the parallel‑line or the slope‑ratio analysis of the standard and the test dose‑response curves, and the 95 % fiducial limits of the estimated potency are reported. This biological determination of calcitonin provides the definitive, legally required measure of the biological activity that cannot be replaced by the physicochemical methods alone, and it is the mandatory release test for every batch of the calcitonin drug substance and the finished product.
- Validation of the assay system and the demonstration of the system suitability: the linearity and the parallelism of the dose‑response curves, the precision of the replicate injections and the accuracy of the recovery of the spiked reference standard are verified in every assay run. The index of precision (λ) and the potency ratio between the standard and the test sample are calculated, and the assay is accepted only if the statistical validity criteria specified in the pharmacopoeia – including the significance of the regression slope, the non‑significance of the deviation from the parallelism and the adequate precision – are satisfied.
- Multi‑point and the reduced‑point assay designs for the different regulatory requirements: the standard three‑dose or four‑dose assay design is used for the definitive potency assignment and the regulatory submission, while the qualified two‑dose design may be employed for the routine stability monitoring, provided that the equivalence of the precision has been demonstrated during the validation, thereby reducing the animal usage and the operational cost while maintaining the full compliance with the pharmacopoeial requirements.
- Cross‑validation with the chemical and the receptor‑binding methods: where the customer has developed an alternative in‑vitro or the physicochemical method – such as the high‑performance liquid chromatography, the immunoassay or the cell‑based receptor‑binding assay – we perform the parallel testing of the same batch by the in‑vivo bioassay and the alternative method, and the correlation coefficient and the agreement between the two methods are reported, supporting the regulatory application for the replacement or the reduction of the animal testing.
- Animal welfare, the ethical review and the compliance with the OECD Principles of Good Laboratory Practice: the biological determination of calcitonin is performed in strict accordance with the national animal‑welfare legislation, the principles of the 3Rs (Replacement, Reduction and Refinement) and the applicable OECD Good Laboratory Practice principles, and the ethical‑review‑committee approval and the animal‑usage records are documented in the study report, ensuring the full traceability and the acceptability of the data by the regulatory authorities.
Report Acceptance and Global Regulatory Compliance
All biological determinations of calcitonin are executed under the fully accredited scope of our ISO/IEC 17025 quality management system. Each test report that carries the ILAC mark is therefore automatically recognised by regulatory authorities, notified bodies, customs offices and supply‑chain partners in all major economies. For pharmaceutical manufacturers, biopharmaceutical developers and contract‑testing organisations anywhere in the world, the report constitutes legally robust, internationally accepted evidence that the calcitonin potency has been determined in accordance with the applicable USP, Ph. Eur. and customer‑specified methods. The documentation can be directly used to support the new‑drug application, the marketing‑authorisation renewal, the issue of inspection certificates according to EN 10204 or equivalent national standards, and the resolution of commercial and technical disputes concerning the biological activity and the batch‑to‑batch consistency of any calcitonin product.
